Consun Pharmaceutical Group Limited (stock code: 01681) has released a Next Day Disclosure Return dated 24 October 2025. The total number of ordinary shares in issue remains at 847,973,407 as of that date, with no treasury shares reported.

According to the disclosure, the company repurchased a series of ordinary shares for cancellation between 14 October and 24 October 2025. A further 100,000 shares were repurchased on 24 October at HKD 15.18 per share, totaling HKD 1,518,000. These repurchased shares have not yet been canceled but remain part of the overall shares in issue as of 24 October 2025.

The report also confirms that 7,306,000 shares have been repurchased under the existing mandate, which authorizes up to 85,126,334 shares to be repurchased. This volume constitutes approximately 8.5825% of the company’s issued share capital at the time the mandate was granted. The moratorium period for any new share issue or treasury share transfer is in effect until 23 November 2025.